Phase I study of photodynamic therapy using talaporfin sodium and diode laser for local failure after chemoradiotherapy for esophageal cancer.

Photodynamic therapy (PDT) is a less invasive and effective salvage treatment for local failure after chemoradiotherapy (CRT) for esophageal cancer, however it causes a high rate of skin phototoxicity and requires a long sun shade period. Talaporfin sodium is a rapidly cleared photosensitizer that is expected to have less phototoxicity.

This study was undertaken to clarify the optimum laser fluence rate of PDT using talaporfin sodium and a diode laser for patients with local failure after CRT or radiotherapy (RT) for esophageal cancer.

Methods: This phase I, laser dose escalation study used a fixed dose (40mg/m2) of intravenous talaporfin sodium administered 4 to 6 hours before irradiation in patients with local failure limited to T2 after CRT or RT (>50 Gy). The primary endpoint was to assess the dose limiting toxicity (DLT) of PDT, and the secondary endpoints were to evaluate the adverse events and toxicity related to PDT.

The starting fluence of the 664nm diode laser was 50 J/cm2, with an escalation plan to 75 J/cm2 and 100 J/cm2.

Results: 9 patients with local failure after CRT or RT for ESCC were enrolled and treated in groups of 3 individuals to the third fluence level. No DLT was observed at any fluence level.

Phototoxicity was not observed, but one subject had grade 1 fever, three had grade 1 esophageal pain, and 1 had grade 1 dysphagia. Five of 9 patients (55.6%) achieved a complete response after PDT.

Conclusions: PDT using talaporfin sodium and a diode laser was safe for local failure after RT in patients with esophageal cancer.

The recommended fluence for the following phase II study is 100J/ cm2.

Author: Tomonori YanoManabu MutoKenichi YoshimuraMiyuki NiimiYasumasa EzoeYusuke YodaYoshinobu YamamotoHogara NishisakiKoji HIgashinoHiroyasu Iishi
Credits/Source: Radiation Oncology 2012, 7:113

Published on: 2012-07-23

Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.

Comments

There are no comments available. Be the first to write a comment.

You need to enable Javascript to post a comment.

Custom Search